247 related articles for article (PubMed ID: 6195275)
41. Human chorionic gonadotropin, its free subunits and gestational trophoblastic disease.
Ozturk M
J Reprod Med; 1991 Jan; 36(1):21-6. PubMed ID: 1706779
[TBL] [Abstract][Full Text] [Related]
42. [Lectin immunoradiometric assay versus improved radioimmunoassay: a comparison of methods for determination of desialylated forms of human chorionic gonadotropin].
Imamura S
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2697-703. PubMed ID: 3003212
[TBL] [Abstract][Full Text] [Related]
43. Serum granulocyte macrophage colony stimulating factor (GM-CSF) in gestational trophoblastic diseases.
Shaarawy M; el-Shobokshy AS; el-Noury AI
Cytokine; 1995 Feb; 7(2):171-5. PubMed ID: 7540057
[TBL] [Abstract][Full Text] [Related]
44. The biochemical properties of urinary human chorionic gonadotropin from the patients with trophoblastic disease.
Nishimura R; Endo Y; Tanabe K; Ashitaka Y; Tojo S
J Endocrinol Invest; 1981; 4(3):349-58. PubMed ID: 7320438
[TBL] [Abstract][Full Text] [Related]
45. Use of an immunoradiometric assay and a radioimmunoassay for the detection of free beta-human chorionic gonadotropin.
Shapiro AI; Wu TF; Ballon SC; Lamb EJ
Obstet Gynecol; 1985 Apr; 65(4):545-9. PubMed ID: 2580254
[TBL] [Abstract][Full Text] [Related]
46. [Studies on the heterogeneity of urinary HCG molecules by RRA and RIA (author's transl)].
Kushiki N; Fuzishima K; Kinoshita T; Ino H; Naka O
Nihon Naibunpi Gakkai Zasshi; 1979 Sep; 55(9):1076-88. PubMed ID: 227758
[TBL] [Abstract][Full Text] [Related]
47. Selecting an appropriate hCG test for managing gestational trophoblastic disease and cancer.
Cole LA; Sutton JM
J Reprod Med; 2004 Jul; 49(7):545-53. PubMed ID: 15305826
[TBL] [Abstract][Full Text] [Related]
48. Monoclonal versus polyclonal antibody radioimmunoassay against the beta-subunit of human chorionic gonadotropin in patients with gestational trophoblastic neoplasia.
Wu T; Ballon SC; Teng NN
Am J Obstet Gynecol; 1983 Dec; 147(7):821-5. PubMed ID: 6196974
[TBL] [Abstract][Full Text] [Related]
49. The heterogeneity of human chorionic gonadotropin (hCG). III. The occurrence and biological and immunological activities of nicked hCG.
Cole LA; Kardana A; Andrade-Gordon P; Gawinowicz MA; Morris JC; Bergert ER; O'Connor J; Birken S
Endocrinology; 1991 Sep; 129(3):1559-67. PubMed ID: 1714836
[TBL] [Abstract][Full Text] [Related]
50. A distinctive form of human chorionic gonadotropin beta-subunit-like material produced by cervical carcinoma cells.
Hussa RO; Fein HG; Pattillo RA; Nagelberg SB; Rosen SW; Weintraub BD; Perini F; Ruddon RW; Cole LA
Cancer Res; 1986 Apr; 46(4 Pt 2):1948-54. PubMed ID: 2418956
[TBL] [Abstract][Full Text] [Related]
51. A comparative study between radioreceptor assay and radioimmunoassay for hCG in patients with trophoblastic disease.
Kletzky OA; Scott JZ; Morrow CP; Mishell DR
Obstet Gynecol; 1978 Sep; 52(3):328-31. PubMed ID: 703989
[TBL] [Abstract][Full Text] [Related]
52. Gestational trophoblastic diseases: 4. Presentation with persistent low positive human chorionic gonadotropin test results.
Cole LA; Khanlian SA; Giddings A; Butler SA; Muller CY; Hammond C; Kohorn E
Gynecol Oncol; 2006 Aug; 102(2):165-72. PubMed ID: 16631243
[TBL] [Abstract][Full Text] [Related]
53. The hCG assay in the treatment of trophoblastic disease.
Pattillo RA; Hussa RO
J Reprod Med; 1984 Nov; 29(11):802-12. PubMed ID: 6097684
[TBL] [Abstract][Full Text] [Related]
54. Clinical use of HCG and hCG beta determinations.
Mann K; Saller B; Hoermann R
Scand J Clin Lab Invest Suppl; 1993; 216():97-104. PubMed ID: 7690985
[TBL] [Abstract][Full Text] [Related]
55. Gestational trophoblastic diseases: 2. Hyperglycosylated hCG as a reliable marker of active neoplasia.
Cole LA; Butler SA; Khanlian SA; Giddings A; Muller CY; Seckl MJ; Kohorn EI
Gynecol Oncol; 2006 Aug; 102(2):151-9. PubMed ID: 16631241
[TBL] [Abstract][Full Text] [Related]
56. Comparison of human chorionic gonadotrophin concentrations in the sera of patients with normal and abnormal pregnancy measured by radio-immunoassay and immunoradiometric assay.
Norman RJ; Buck RH; Joubert SM
S Afr Med J; 1989 Apr; 75(7):318-9. PubMed ID: 2538933
[TBL] [Abstract][Full Text] [Related]
57. [The determination of the recognition site of an antiserum detecting desialylation on O-glycosidic carbohydrates of hCG and its clinical applications. The relationship between the presence of asialo-hCG and malignant change in trophoblastic disease].
Takeuchi Y; Matsuura S; Nishimura R; Mochizuki M
Nihon Naibunpi Gakkai Zasshi; 1984 Sep; 60(9):1046-57. PubMed ID: 6097485
[TBL] [Abstract][Full Text] [Related]
58. Predicting gestational trophoblastic neoplasia (GTN): is urine hCG the answer?
Alazzam M; Young T; Coleman R; Hancock B; Drew D; Wilson P; Tidy J
Gynecol Oncol; 2011 Sep; 122(3):595-9. PubMed ID: 21684585
[TBL] [Abstract][Full Text] [Related]
59. Serum SP1 and hCG beta-subunit (hCG beta) levels in choriocarcinoma, invasive mole, and hydatidiform mole--clinical significance of SP1/hCG beta ratio.
Sakuragi N
Gynecol Oncol; 1982 Jun; 13(3):393-8. PubMed ID: 6178652
[No Abstract] [Full Text] [Related]
60. [Evaluation of remission in trophoblastic disease as seen from serum hCG level (author's transl)].
Hirashima N
Nihon Sanka Fujinka Gakkai Zasshi; 1980 May; 32(5):592-600. PubMed ID: 6263999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
